Insulet Corporation (PODD) is a medical technology company dedicated to improving the lives of individuals with diabetes and other conditions requiring daily insulin therapy. Its primary activity is the design, development, and commercialization of the Omnipod system, a proprietary insulin delivery platform. Unlike traditional insulin pump technologies, Insulet focuses on the innovation of disposable, tubeless, wearable devices that provide consistent, automated insulin administration. The company’s business model is centered on a recurring revenue cycle, where patients purchase the initial controller hardware and then consistently replace the disposable pods every few days. By combining high-precision medical hardware with sophisticated, user-friendly mobile software, the company effectively acts as a critical partner in global diabetes management, focusing on increasing patient autonomy, simplifying insulin delivery, and reducing the long-term clinical burden of daily glucose management.